Company intelligence / Profile preview
Eos Biosciences
Los Angeles, California, United Stateseosbiosciences.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Eos Biosciences was a bio-pharmaceutical company focused on the development of targeted medicines for the treatment of cancer. The company's primary technology platform, Eos-002, was a proprietary HER3-targeted antibody-drug conjugate (ADC) delivery vehicle designed to improve the therapeutic index of potent chemotherapeutic agents. By targeting the HER3 receptor, which is overexpressed in many solid tumors, Eos aimed to deliver high concentrations of drugs directly to cancer cells while minimizing systemic toxicity. The company was acquired by Bionaut Labs in 2021 to integrate its targeting technology into micro-robotic delivery systems.
- Therapeutic areas
- Oncology
- Modalities
- Antibody-drug conjugateNanoparticle
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Eos Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Eos Biosciences.